For Life Sciences Teams

From testing strategy to FDA submission,
accurate drafts in less time.

Whether you're bringing a medical device, drug, or biologic to market — Deffai gives you the regulatory infrastructure to move with transparency, predictability, and former FDA reviewer oversight from day one.

For Human Cells and Tissue-Based Products (HCT/P)

For Drugs & Biologics

For Medical Devices

01

361 HCT/P Regulatory Assessment

Validate your product's 361 HCT/P regulatory status with confidence. Our AI-powered assessment, built by ex-TRG reviewers with experience on 400+ submissions, delivers a complete 361 determination in 24 hours — catching classification errors before the FDA does.

Get Your 361 Assessment
100% Deffai accuracy
~73% Generic AI accuracy
24 hrs Turnaround
  • Five-gate regulatory analysis: HCT/P status, exceptions, 21 CFR 1271.10(a) four-criterion test, labeling, and warning letter risk
  • Benchmarked against GPT, Claude, and Gemini — Deffai delivers 100% accuracy where generic AI averages 73%
  • FDA enforcement landscape analysis — flags warning letter patterns relevant to your product
  • Expert-reviewed DOCX report with cited findings, delivered in 24 hours
  • Built by former TRG reviewers who know exactly what goes behind FDA decision logic
02

INTERACT Meeting Preparation

End-to-end preparation for your INTERACT meeting with CBER. From readiness assessment and meeting type triage to briefing package generation, question scoring, and mock Q&A — so you walk into the FDA's earliest formal engagement fully prepared.

Prepare Your INTERACT Meeting
~47% FDA rejection rate
10 Max questions
50 pages Package limit
  • Readiness assessment — determines if INTERACT is the right meeting type vs. Pre-IND or Type D
  • AI-drafted 50-page briefing package with CMC, pharmacology/toxicology, and clinical sections
  • Question quality scoring — flags vague or overly broad questions that trigger FDA rejection
  • Precedent analysis from our biologics corpus of BLA approvals, supplements, and FDA guidance
  • Mock Q&A preparation based on historical FDA meeting patterns and review posture
  • Former FDA reviewer reviews every deliverable before it reaches you

See Deffai
in action.

Whether you're validating a 361 HCT/P classification or preparing for your first INTERACT meeting, our former FDA reviewers will show you exactly how Deffai accelerates your regulatory path.

No commitment required  ·  Speak directly with a former FDA reviewer